Filtered By:
Therapy: Radiation Therapy
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 256 results found since Jan 2013.
SMART Syndrome (Stroke-like migraine attacks after radiation therapy): When to suspect it?
CONCLUSION: The triad of migraine, seizure, and hemiparesis within the context of a prior brain radiotherapy should promptly raise the suspicion of SMART syndrome. Prompt diagnosis is essential to avoid unnecessary invasive investigations.PMID:34877047 | PMC:PMC8645481 | DOI:10.25259/SNI_893_2021
Source: Surgical Neurology International - December 8, 2021 Category: Neurosurgery Authors: Petros Angelidis Christian Saleh Phillip Jaszczuk Muhannad Seyam Katarina Alexandra Ebner Margret Hund-Georgiadis Source Type: research
ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news
O-032 Treatment outcomes for ARUBA eligible brain arteriovenous malformations: a comparison of real world data from the NVQI-QOD AVM registry to the ARUBA trial
ConclusionARUBA eligible patients from the NVQI-QOD registry demonstrate a significantly lower risk of stroke or death with intervention of 8.0% (N=174) compared to the 30.7% (N=114) ARUBA trial interventional risk, and is nearly equivalent to the ARUBA trial medical management risk of 10.1% (N=109) over 33 months.Disclosures N. Moore: 1; C; SNIS Joe Niekro Research Grant. R. Abdalla: None. T. Patterson: None. Y. Moazeni: None. P. Rasmussen: 2; C; Blockade Medical, Covidien/Medtronic, Stryker Neurovascular, Perflow Medical. 4; C; Perflow Medical. G. Toth: None. M. Bain: 2; C; Stryker Neurovascular. S. Ansari: None. S. Huss...
Source: Journal of NeuroInterventional Surgery - July 26, 2021 Category: Neurosurgery Authors: Moore, N., Abdalla, R., Patterson, T., Moazeni, Y., Rasmussen, P., Toth, G., Bain, M., Ansari, S., Hussain, S. Tags: Oral abstracts Source Type: research
Late vascular complications after cranial radiotherapy: A report of two illustrative cases
We present two cases of late neurological complications after CRT and briefly discuss its diagnosis and their shared pathophysiological aspects. The first case is a patient with cognitive impairment associated to mineralizing microangiopathy ten years after CRT for nasopharyngeal carcinoma and the second one is a woman with Stroke-like Migraine Attacks after Radiation Therapy (SMART) syndrome two years after CRT for anaplastic meningioma. Nowadays, higher survival rates might cause an increase in appearance of late neurological complications after CTR. These reported cases show that late complications can mimic a wide vari...
Source: Cancer Radiotherapie - April 27, 2021 Category: Cancer & Oncology Authors: J Madera A S ánchez-Soblechero P Navarrete Solano U Corro Verde E Marco de Lucas M Pacheco Baldor P J Prada J Pascual Source Type: research
